EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Klinische Studie (Phase IV)Open Access · CC BY-NC 4.0

Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open‐label FIRST study

Mona Hamdy iD, Amal El-Beshlawy, Mônica P A Veríssimo, Julie Kanter iD, Baba Inusa iD, Suzan Williams, David Lee, Noemi Toiber Temin, Caroline Fradette, Fernando Tricta, Fatma S E Ebeid iD, Janet L Kwiatkowski und 1 weitere

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30711 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Mona Hamdy und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, beta-Thalassemia, Iron Overload, Neutropenia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Children with sickle cell disease (SCD) who are chronically transfused often, require iron chelation therapy. There are limited data that allow for comparison of the efficacy and safety of the iron chelator deferiprone versus deferoxamine in children with SCD.

Methods

This post hoc analysis of the phase 3b/4, randomized, open‐label FIRST ( F erriprox in Patients with IR on Overload in S ickle Cell Disease T rial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine.

Results

Overall, 142 patients were evaluated; mean ages were 10.5 and 11.7 years in the deferiprone and deferoxamine groups, respectively. At 12 months: mean change from baseline in liver iron concentration was −3.3 mg/g dry weight (dw) with deferiprone and −3.4 mg/g dw with deferoxamine ( p = .8216); relative mean change (coefficient of variation %) in log cardiac T2* magnetic resonance imaging was 1.02 (21.8%) with deferiprone and 0.95 (19.5%) with deferoxamine ( p = .0717); and the mean (standard error) change in serum ferritin levels was −133.0 (200.3) μg/L with deferiprone and −467.1 (244.1) μg/L with deferoxamine ( p = .2924). The most common deferiprone‐related adverse events (AEs) were upper abdominal pain (20.2%), vomiting (13.8%), pyrexia (9.6%), decreased neutrophil count (9.6%), increased alanine aminotransferase (ALT; 9.6%), and increased aspartate aminotransferase (AST; 9.6%). All cases of increased ALT, increased AST, and neutropenia resolved, most without intervention.

Conclusions

This post hoc analysis of pediatric patients from FIRST corroborated previous findings in adults that deferiprone is comparable to deferoxamine in reducing iron overload. No new safety concerns were observed. Deferiprone is an oral chelation option that could improve adherence and outcomes in children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle Cellbeta-ThalassemiaIron OverloadNeutropeniaAdultChildHumansDeferiproneDeferoxamineIronIron Chelating AgentsPyridones

Stichwörter der Autor:innen

chelationdeferipronedeferoxamineiron overloadpediatricsickle cell disease

Substanzen

DeferiproneDeferoxamineIronIron Chelating AgentsPyridones

Autor:innen und Institutionen

  • Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt.
  • Department of Pediatric Hematology, Pediatric Hospital of Cairo University, Cairo, Egypt.
  • Centro Infantil Boldrini, São Paulo, Brazil.
  • Division of Hematology and Oncology, Department of Medicine, University of Alabama, Birmingham, Alabama, USA.
  • Paediatric Haematology, Evelina Children's Hospital, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Department of Haematology and Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Mona Hamdy, Julie Kanter, Baba Inusa, Fatma S E Ebeid

Förderung

  • NCATS NIH HHS
  • NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institutes of Health

Zitieren

APA

Hamdy, M., El-Beshlawy, A., Veríssimo, M. P. A., Kanter, J., Inusa, B., Williams, S., Lee, D., Temin, N. T., Fradette, C., Tricta, F., Ebeid, F. S. E., Kwiatkowski, J. L., & Elalfy, M. S. (2024). Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open‐label FIRST study. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30711

Vancouver

Hamdy M, El-Beshlawy A, Veríssimo MPA, Kanter J, Inusa B, Williams S, et al. Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open‐label FIRST study. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30711

BibTeX
@article{Hamdy2024,
  author = {Hamdy, Mona and El-Beshlawy, Amal and Veríssimo, Mônica P A and Kanter, Julie and Inusa, Baba and Williams, Suzan and Lee, David and Temin, Noemi Toiber and Fradette, Caroline and Tricta, Fernando and Ebeid, Fatma S E and Kwiatkowski, Janet L and Elalfy, Mohsen S},
  title = {Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open‐label FIRST study},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30711}
}
Kostenlos starten →